SpectraPure Bevelite

Updated: 2026-07-18

Overview

Bevirimat (PA-457) is a first-in-class HIV-1 maturation inhibitor discovered through the modification of betulinic acid. As an experimental antiretroviral compound, it uniquely targets the final step of HIV-1 viral processing by inhibiting the cleavage of the CA-SP1 junction in Gag polyprotein. Originally developed by Panacos Pharmaceuticals, Bevirimat showed promise in early clinical trials but faced challenges due to polymorphic variations in HIV-1 strains. It remains an important research tool for studying HIV maturation mechanisms and continues to inform the development of next-generation maturation inhibitors.

Physical and Chemical Properties

Bevirimat is a white crystalline powder with moderate solubility in organic solvents but limited water solubility. Its molecular structure features a modified betulinic acid core with added functional groups that enhance its antiviral activity and pharmacokinetic properties. The compound demonstrates stability under recommended storage conditions but may degrade when exposed to light, heat, or moisture. Analytical characterization typically employs HPLC and mass spectrometry techniques to verify purity, which is crucial for research applications where compound integrity directly impacts experimental outcomes.

Main Applications

In research settings, Bevirimat serves two primary purposes: as a tool compound for studying HIV-1 maturation processes and as a lead structure for developing improved maturation inhibitors. Its unique mechanism makes it valuable for investigating viral capsid assembly and maturation pathways. Pharmaceutical researchers also study Bevirimat's potential in combination therapies, particularly for treatment-experienced patients with multi-drug resistant HIV. While clinical development was discontinued, insights from Bevirimat research continue to inform new antiretroviral drug discovery programs targeting the viral maturation stage.

Safety and Storage

As a research chemical, Bevirimat requires careful handling in laboratory environments. Standard precautions include using gloves, lab coats, and eye protection when working with the powder form. All procedures should be conducted in properly ventilated areas or fume hoods. For long-term storage, maintain the compound in its original packaging at 2-8°C with desiccant packs to prevent moisture absorption. Aliquot larger quantities to minimize repeated exposure to ambient conditions. Dispose of waste according to institutional guidelines for pharmaceutical compounds.

B2B Procurement Guide

Procuring Bevirimat requires navigating specialized pharmaceutical supply chains. Most suppliers cater exclusively to research institutions and require documentation verifying legitimate research use. Lead times can vary significantly depending on supplier inventory and regulatory clearance requirements. When evaluating suppliers, prioritize those providing comprehensive analytical certificates (CoA) with each batch, including HPLC purity profiles and mass spectrometry confirmation. Consider ordering small test quantities first to verify compound quality before committing to larger purchases. International shipments may require special permits due to controlled substance regulations in some jurisdictions.